 George Wang
Concepts (289)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cannabis | 28 | 2024 | 461 | 7.160 |
Why?
| | Poison Control Centers | 12 | 2022 | 88 | 4.600 |
Why?
| | Drug Overdose | 9 | 2022 | 326 | 3.380 |
Why?
| | Legislation, Drug | 7 | 2021 | 77 | 2.900 |
Why?
| | Medical Marijuana | 5 | 2022 | 111 | 2.730 |
Why?
| | Hallucinogens | 6 | 2024 | 102 | 2.560 |
Why?
| | Marijuana Use | 5 | 2019 | 191 | 2.430 |
Why?
| | Marijuana Smoking | 9 | 2024 | 247 | 2.260 |
Why?
| | Marijuana Abuse | 5 | 2024 | 233 | 2.200 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 919 | 2.110 |
Why?
| | Dronabinol | 11 | 2024 | 203 | 2.030 |
Why?
| | Emergency Service, Hospital | 15 | 2021 | 1918 | 1.910 |
Why?
| | Poisoning | 7 | 2021 | 111 | 1.820 |
Why?
| | Hospitals, Pediatric | 9 | 2022 | 514 | 1.780 |
Why?
| | Cannabinoids | 6 | 2023 | 154 | 1.760 |
Why?
| | Nonprescription Drugs | 4 | 2022 | 66 | 1.670 |
Why?
| | Drug Packaging | 3 | 2018 | 41 | 1.640 |
Why?
| | Diphenhydramine | 6 | 2022 | 31 | 1.580 |
Why?
| | Poisons | 2 | 2022 | 20 | 1.510 |
Why?
| | Hypotension | 4 | 2022 | 117 | 1.430 |
Why?
| | Cough | 3 | 2022 | 117 | 1.420 |
Why?
| | Vomiting | 3 | 2021 | 129 | 1.380 |
Why?
| | Eating | 7 | 2023 | 371 | 1.330 |
Why?
| | Substance-Related Disorders | 4 | 2019 | 1022 | 1.290 |
Why?
| | Child | 36 | 2023 | 20932 | 1.180 |
Why?
| | Substance Abuse Detection | 5 | 2024 | 79 | 1.180 |
Why?
| | Child, Preschool | 24 | 2023 | 10499 | 1.090 |
Why?
| | Epilepsy | 3 | 2020 | 322 | 1.090 |
Why?
| | Prescription Drugs | 2 | 2020 | 109 | 1.080 |
Why?
| | Humans | 83 | 2024 | 129527 | 1.050 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2022 | 122 | 1.020 |
Why?
| | Antitussive Agents | 3 | 2021 | 7 | 1.020 |
Why?
| | Medication Errors | 2 | 2019 | 96 | 0.990 |
Why?
| | Colorado | 16 | 2023 | 4403 | 0.980 |
Why?
| | Adolescent | 29 | 2024 | 20409 | 0.950 |
Why?
| | Infant | 21 | 2022 | 9005 | 0.940 |
Why?
| | Muscarinic Antagonists | 2 | 2022 | 27 | 0.900 |
Why?
| | Dextromethorphan | 3 | 2021 | 18 | 0.870 |
Why?
| | Oxycodone | 2 | 2021 | 43 | 0.860 |
Why?
| | Eyelids | 1 | 2024 | 34 | 0.860 |
Why?
| | Multi-Ingredient Cold, Flu, and Allergy Medications | 2 | 2020 | 3 | 0.840 |
Why?
| | Fentanyl | 2 | 2021 | 81 | 0.840 |
Why?
| | Ambulatory Care | 4 | 2021 | 507 | 0.830 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2022 | 244 | 0.800 |
Why?
| | Phytotherapy | 2 | 2013 | 78 | 0.790 |
Why?
| | Psychotropic Drugs | 2 | 2021 | 69 | 0.790 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2022 | 14 | 0.760 |
Why?
| | Cannabidiol | 2 | 2022 | 108 | 0.760 |
Why?
| | Fractures, Closed | 1 | 2022 | 17 | 0.760 |
Why?
| | Retrospective Studies | 20 | 2022 | 14532 | 0.760 |
Why?
| | Female | 42 | 2024 | 68650 | 0.740 |
Why?
| | Bupropion | 1 | 2021 | 40 | 0.720 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 108 | 0.720 |
Why?
| | United States | 17 | 2024 | 13865 | 0.720 |
Why?
| | Physostigmine | 1 | 2020 | 12 | 0.710 |
Why?
| | Akathisia, Drug-Induced | 1 | 2020 | 6 | 0.710 |
Why?
| | Acute Pain | 1 | 2021 | 48 | 0.700 |
Why?
| | Lorazepam | 1 | 2020 | 26 | 0.700 |
Why?
| | Anesthesia | 1 | 2023 | 172 | 0.700 |
Why?
| | Arrhythmias, Cardiac | 2 | 2022 | 321 | 0.670 |
Why?
| | Psychotic Disorders | 1 | 2022 | 150 | 0.660 |
Why?
| | Male | 35 | 2024 | 63586 | 0.660 |
Why?
| | Clenbuterol | 1 | 2019 | 4 | 0.650 |
Why?
| | Common Cold | 1 | 2019 | 13 | 0.650 |
Why?
| | Black Widow Spider | 1 | 2019 | 9 | 0.640 |
Why?
| | Delirium | 1 | 2020 | 77 | 0.640 |
Why?
| | Spider Venoms | 1 | 2019 | 11 | 0.640 |
Why?
| | Designer Drugs | 1 | 2019 | 8 | 0.620 |
Why?
| | Bradycardia | 2 | 2023 | 53 | 0.620 |
Why?
| | Biguanides | 1 | 2018 | 12 | 0.600 |
Why?
| | Plant Extracts | 1 | 2020 | 198 | 0.590 |
Why?
| | Anticonvulsants | 1 | 2020 | 209 | 0.590 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 1 | 2018 | 9 | 0.590 |
Why?
| | Child Abuse | 2 | 2022 | 513 | 0.570 |
Why?
| | Face | 1 | 2019 | 165 | 0.570 |
Why?
| | Schizophrenia | 1 | 2022 | 425 | 0.570 |
Why?
| | Capsaicin | 1 | 2017 | 25 | 0.570 |
Why?
| | Tertiary Care Centers | 2 | 2017 | 153 | 0.560 |
Why?
| | Mass Spectrometry | 1 | 2021 | 717 | 0.560 |
Why?
| | Antiemetics | 1 | 2017 | 41 | 0.550 |
Why?
| | Tachycardia | 2 | 2019 | 57 | 0.540 |
Why?
| | Accidents, Home | 1 | 2017 | 29 | 0.540 |
Why?
| | Acetaminophen | 3 | 2022 | 248 | 0.540 |
Why?
| | Drug Storage | 1 | 2017 | 58 | 0.540 |
Why?
| | Emergency Medicine | 1 | 2019 | 217 | 0.530 |
Why?
| | Emergency Services, Psychiatric | 1 | 2017 | 31 | 0.530 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 26 | 0.520 |
Why?
| | Renal Insufficiency | 1 | 2018 | 149 | 0.520 |
Why?
| | Acetylcysteine | 2 | 2022 | 145 | 0.510 |
Why?
| | Narcotic Antagonists | 1 | 2018 | 164 | 0.510 |
Why?
| | Buprenorphine | 1 | 2020 | 162 | 0.510 |
Why?
| | Fractures, Bone | 1 | 2021 | 395 | 0.510 |
Why?
| | Seizures | 1 | 2019 | 402 | 0.490 |
Why?
| | Hyperammonemia | 1 | 2015 | 16 | 0.480 |
Why?
| | Methanol | 1 | 2015 | 35 | 0.480 |
Why?
| | Food | 1 | 2016 | 155 | 0.470 |
Why?
| | Hospitalization | 3 | 2022 | 2076 | 0.470 |
Why?
| | Metformin | 1 | 2018 | 316 | 0.460 |
Why?
| | Toxicology | 1 | 2015 | 41 | 0.450 |
Why?
| | Electrocardiography | 2 | 2019 | 612 | 0.450 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 231 | 0.450 |
Why?
| | Students | 1 | 2019 | 581 | 0.420 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.420 |
Why?
| | Plant Preparations | 1 | 2013 | 32 | 0.420 |
Why?
| | Accidents | 1 | 2013 | 38 | 0.410 |
Why?
| | Risk Assessment | 3 | 2017 | 3255 | 0.410 |
Why?
| | Plasmapheresis | 1 | 2013 | 22 | 0.410 |
Why?
| | Amphotericin B | 1 | 2013 | 30 | 0.410 |
Why?
| | Ethers | 1 | 2012 | 16 | 0.400 |
Why?
| | Flecainide | 1 | 2012 | 7 | 0.390 |
Why?
| | Asymptomatic Diseases | 1 | 2013 | 84 | 0.390 |
Why?
| | Adult | 14 | 2024 | 35505 | 0.390 |
Why?
| | Antifungal Agents | 1 | 2013 | 130 | 0.380 |
Why?
| | Medication Adherence | 1 | 2017 | 560 | 0.380 |
Why?
| | Pharmacy | 1 | 2012 | 31 | 0.380 |
Why?
| | Drug Compounding | 1 | 2012 | 97 | 0.380 |
Why?
| | Tertiary Healthcare | 2 | 2021 | 31 | 0.380 |
Why?
| | Acid-Base Equilibrium | 2 | 2022 | 27 | 0.370 |
Why?
| | Tremor | 2 | 2024 | 60 | 0.370 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 83 | 0.350 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 29 | 0.350 |
Why?
| | Referral and Consultation | 2 | 2021 | 732 | 0.350 |
Why?
| | Hospital Rapid Response Team | 1 | 2010 | 17 | 0.350 |
Why?
| | Cannabinoid Receptor Agonists | 4 | 2023 | 46 | 0.340 |
Why?
| | Health Facilities | 2 | 2022 | 80 | 0.340 |
Why?
| | Population Surveillance | 1 | 2013 | 440 | 0.340 |
Why?
| | Liver Failure | 1 | 2011 | 91 | 0.340 |
Why?
| | Antidotes | 2 | 2022 | 136 | 0.340 |
Why?
| | Practice Patterns, Physicians' | 4 | 2023 | 1257 | 0.340 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 761 | 0.340 |
Why?
| | Antivenins | 2 | 2020 | 35 | 0.330 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1219 | 0.320 |
Why?
| | Acidosis | 2 | 2021 | 89 | 0.300 |
Why?
| | Pediatrics | 2 | 2017 | 1068 | 0.280 |
Why?
| | Suicide, Attempted | 1 | 2011 | 356 | 0.280 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 611 | 0.280 |
Why?
| | Incidence | 3 | 2021 | 2643 | 0.260 |
Why?
| | Tandem Mass Spectrometry | 3 | 2022 | 525 | 0.260 |
Why?
| | Young Adult | 7 | 2024 | 12438 | 0.250 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.240 |
Why?
| | Half-Life | 2 | 2019 | 162 | 0.240 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 5078 | 0.240 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2421 | 0.220 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2019 | 203 | 0.220 |
Why?
| | Analgesics | 2 | 2023 | 194 | 0.220 |
Why?
| | Case-Control Studies | 2 | 2022 | 3383 | 0.190 |
Why?
| | Hemodiafiltration | 1 | 2022 | 9 | 0.190 |
Why?
| | Public Health | 3 | 2024 | 484 | 0.190 |
Why?
| | Infant, Newborn | 3 | 2021 | 5769 | 0.180 |
Why?
| | Prevalence | 2 | 2019 | 2561 | 0.180 |
Why?
| | Prescriptions | 1 | 2021 | 67 | 0.180 |
Why?
| | Infusions, Intravenous | 2 | 2013 | 402 | 0.180 |
Why?
| | Length of Stay | 3 | 2021 | 1132 | 0.180 |
Why?
| | Databases, Factual | 3 | 2021 | 1261 | 0.180 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2023 | 235 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2024 | 2013 | 0.170 |
Why?
| | Snake Bites | 1 | 2020 | 28 | 0.170 |
Why?
| | Syndrome | 1 | 2021 | 338 | 0.170 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2020 | 59 | 0.170 |
Why?
| | Anti-Anxiety Agents | 1 | 2020 | 45 | 0.170 |
Why?
| | Hospitals | 2 | 2023 | 649 | 0.170 |
Why?
| | Heart Rate | 1 | 2024 | 804 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2022 | 242 | 0.170 |
Why?
| | Heart Arrest | 1 | 2023 | 323 | 0.160 |
Why?
| | Flank Pain | 1 | 2019 | 9 | 0.160 |
Why?
| | Performance-Enhancing Substances | 1 | 2019 | 9 | 0.160 |
Why?
| | Milk, Human | 1 | 2021 | 151 | 0.160 |
Why?
| | Public Health Surveillance | 1 | 2019 | 68 | 0.160 |
Why?
| | Poisson Distribution | 1 | 2019 | 73 | 0.160 |
Why?
| | Temperature | 1 | 2022 | 635 | 0.160 |
Why?
| | Cardiotoxicity | 1 | 2019 | 33 | 0.160 |
Why?
| | Self Report | 2 | 2024 | 800 | 0.150 |
Why?
| | Biological Availability | 1 | 2019 | 147 | 0.150 |
Why?
| | Treatment Outcome | 4 | 2020 | 10232 | 0.150 |
Why?
| | Morphine | 1 | 2020 | 138 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2019 | 37 | 0.150 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3081 | 0.150 |
Why?
| | Methadone | 1 | 2020 | 92 | 0.150 |
Why?
| | Epidemics | 1 | 2020 | 82 | 0.150 |
Why?
| | Hyperlactatemia | 1 | 2018 | 3 | 0.150 |
Why?
| | Adrenergic beta-Agonists | 1 | 2019 | 133 | 0.150 |
Why?
| | Drug Utilization | 1 | 2019 | 170 | 0.150 |
Why?
| | Tissue Distribution | 1 | 2019 | 315 | 0.150 |
Why?
| | Adolescent Health | 1 | 2018 | 39 | 0.150 |
Why?
| | Prospective Studies | 3 | 2021 | 7150 | 0.150 |
Why?
| | Vulnerable Populations | 1 | 2019 | 155 | 0.150 |
Why?
| | Administration, Topical | 1 | 2017 | 147 | 0.140 |
Why?
| | Urine | 1 | 2017 | 60 | 0.140 |
Why?
| | Risk Factors | 4 | 2017 | 9779 | 0.140 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 376 | 0.130 |
Why?
| | Physical Examination | 1 | 2018 | 233 | 0.130 |
Why?
| | Health Surveys | 1 | 2019 | 493 | 0.130 |
Why?
| | Administration, Oral | 1 | 2019 | 783 | 0.130 |
Why?
| | Regression Analysis | 1 | 2019 | 994 | 0.130 |
Why?
| | Pregnancy | 2 | 2022 | 6412 | 0.130 |
Why?
| | Physician's Role | 1 | 2018 | 203 | 0.130 |
Why?
| | Preventive Health Services | 1 | 2018 | 144 | 0.130 |
Why?
| | Universities | 1 | 2019 | 406 | 0.130 |
Why?
| | Pain Management | 1 | 2019 | 330 | 0.130 |
Why?
| | Double-Blind Method | 1 | 2020 | 1873 | 0.130 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 515 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 206 | 0.120 |
Why?
| | Middle Aged | 5 | 2024 | 31087 | 0.120 |
Why?
| | Tea Tree Oil | 1 | 2015 | 2 | 0.120 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 87 | 0.120 |
Why?
| | Child Behavior | 1 | 2017 | 235 | 0.120 |
Why?
| | Glasgow Coma Scale | 1 | 2015 | 165 | 0.110 |
Why?
| | Parents | 2 | 2021 | 1309 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2015 | 300 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 89 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1018 | 0.110 |
Why?
| | Pulmonary Surfactants | 1 | 2015 | 106 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1500 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 4 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 26 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 539 | 0.110 |
Why?
| | Clinical Enzyme Tests | 1 | 2013 | 10 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2018 | 507 | 0.100 |
Why?
| | Salicylates | 1 | 2013 | 30 | 0.100 |
Why?
| | Blood Cell Count | 1 | 2013 | 52 | 0.100 |
Why?
| | Spasm | 1 | 2013 | 20 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Urinalysis | 1 | 2013 | 75 | 0.100 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2013 | 40 | 0.100 |
Why?
| | Blood Chemical Analysis | 1 | 2013 | 97 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 326 | 0.100 |
Why?
| | Mycoses | 1 | 2013 | 73 | 0.100 |
Why?
| | Osmolar Concentration | 2 | 2022 | 167 | 0.100 |
Why?
| | Logistic Models | 1 | 2017 | 1983 | 0.090 |
Why?
| | Cohort Studies | 1 | 2022 | 5423 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 329 | 0.090 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2015 | 285 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 312 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 20 | 0.090 |
Why?
| | Medical Audit | 1 | 2011 | 73 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 199 | 0.090 |
Why?
| | International Normalized Ratio | 1 | 2011 | 46 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1422 | 0.090 |
Why?
| | Kidney | 1 | 2018 | 1382 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 112 | 0.090 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 484 | 0.090 |
Why?
| | Mass Screening | 1 | 2018 | 1186 | 0.090 |
Why?
| | Alanine Transaminase | 1 | 2011 | 154 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 83 | 0.080 |
Why?
| | Age Factors | 1 | 2017 | 3150 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 6530 | 0.080 |
Why?
| | Survival Rate | 1 | 2013 | 1870 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 763 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 423 | 0.080 |
Why?
| | Mental Disorders | 1 | 2017 | 1026 | 0.070 |
Why?
| | Suicide | 1 | 2015 | 613 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1001 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 2225 | 0.070 |
Why?
| | Primary Health Care | 1 | 2018 | 1677 | 0.070 |
Why?
| | Pain | 1 | 2013 | 788 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5429 | 0.070 |
Why?
| | Animals | 3 | 2020 | 35334 | 0.070 |
Why?
| | Kidney Transplantation | 1 | 2013 | 669 | 0.060 |
Why?
| | Depression | 1 | 2015 | 1321 | 0.060 |
Why?
| | Emergency Medical Services | 1 | 2011 | 521 | 0.060 |
Why?
| | Digoxin | 1 | 2023 | 28 | 0.050 |
Why?
| | Benzodiazepines | 1 | 2023 | 138 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 673 | 0.050 |
Why?
| | Toxicokinetics | 1 | 2022 | 9 | 0.050 |
Why?
| | Valproic Acid | 1 | 2022 | 47 | 0.050 |
Why?
| | Brompheniramine | 1 | 2021 | 2 | 0.050 |
Why?
| | Doxylamine | 1 | 2021 | 2 | 0.050 |
Why?
| | Guaifenesin | 1 | 2021 | 2 | 0.050 |
Why?
| | Pseudoephedrine | 1 | 2021 | 2 | 0.050 |
Why?
| | Chlorpheniramine | 1 | 2021 | 6 | 0.050 |
Why?
| | American Heart Association | 1 | 2023 | 300 | 0.050 |
Why?
| | Phenylephrine | 1 | 2021 | 75 | 0.050 |
Why?
| | Drug Labeling | 1 | 2021 | 38 | 0.050 |
Why?
| | Follow-Up Studies | 1 | 2010 | 4891 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2023 | 320 | 0.050 |
Why?
| | Homicide | 1 | 2021 | 61 | 0.040 |
Why?
| | Crotalus | 1 | 2020 | 26 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2023 | 245 | 0.040 |
Why?
| | Crotalid Venoms | 1 | 2020 | 31 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 424 | 0.040 |
Why?
| | Health Care Costs | 1 | 2021 | 366 | 0.040 |
Why?
| | Research Design | 1 | 2024 | 1043 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 23 | 0.040 |
Why?
| | Models, Biological | 1 | 2024 | 1717 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 584 | 0.030 |
Why?
| | Safety | 1 | 2017 | 335 | 0.030 |
Why?
| | Deglutition | 1 | 2015 | 67 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1902 | 0.030 |
Why?
| | Biomarkers | 1 | 2023 | 3968 | 0.020 |
Why?
|
|
Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|